Dolutegravir with recycled Nucleoside Reverse Transcriptase Inhibitors maintains better viral suppression than Protease Inhibitor based Antiretroviral therapy over 144 weeks: VISEND Trial

被引：0
|
作者：
Sivile, S. [1 ,2 ,3 ]
Fwoloshi, S. [1 ,2 ,3 ]
Engamba, D. [1 ,4 ]
Mweemba, A. [1 ,4 ]
Siwingwa, M. [1 ,3 ]
Kampamba, D. [1 ,2 ]
Mbewe, M. [1 ]
Kumar, A. P. [1 ]
Mbewe, N. [1 ,5 ]
Phiri, H. [2 ]
Shibemba, A. [1 ]
Haabanji, B. P. [1 ]
Mwamba, E. [1 ]
Simons, B. [6 ]
Wester, C. W. [7 ,8 ]
Chirwa, L. [1 ]
Hill, A. [9 ]
Mulenga, L. [1 ,2 ,3 ,7 ,8 ]
机构：
[1] Univ Teaching Hosp, Adult Infect Dis Ctr, Lusaka, Zambia
[2] Minist Hlth, Div Infect Dis, Lusaka, Zambia
[3] Univ Zambia, Sch Med, Div Infect Dis, Lusaka, Zambia
[4] Levy Mwanawasa Med Univ, Div Infect Dis, Lusaka, Zambia
[5] Zambia Natl Publ Hlth Inst, Lusaka, Zambia
[6] London Sch Econ & Polit Sci, London, Zambia
[7] Vanderbilt Inst Global Hlth, Nashville, TN USA
[8] Vanderbilt Univ, Med Ctr, Dept Med, Div Infect Dis, Nashville, TN USA
[9] Univ Liverpool, Dept Translat Med, Liverpool, Merseyside, England
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2024年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
OAB3806LB
引用
收藏
页码：91 / 92
页数：2
相关论文
共 29 条
  • [1] Incident tuberculosis as a risk factor for viral non-suppression 48 weeks among patients switched to dolutegravir based therapy with recycled nucleoside reverse transcriptase inhibitors in Lusaka, Zambia
    Mbewe, N.
    Engamba, D.
    Fwoloshi, S.
    Mulenga, L.
    Lakhi, S.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 217 - 218
  • [2] Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients
    Chen, Guan-Jhou
    Sun, Hsin-Yun
    Chang, Sui-Yuan
    Cheng, Aristine
    Huang, Yu-Shan
    Lin, Kuan-Yin
    Huang, Yi-Chia
    Su, Yi-Ching
    Liu, Wen-Chun
    Hung, Chien-Ching
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 54 (01) : 35 - 42
  • [3] Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone
    Waters, Laura
    Bansi, Loveleen
    Asboe, David
    Pozniak, Anton
    Smit, Erasmus
    Orkin, Chloe
    Fearnhill, Esther
    Dunn, David
    Phillips, Andrew
    ANTIVIRAL THERAPY, 2013, 18 (02) : 213 - 219
  • [4] Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens
    Trotta, MP
    Ammassari, A
    Cozzi-Lepri, A
    Zaccarelli, M
    Castelli, F
    Narciso, P
    Melzi, S
    De Luca, A
    Monforte, AD
    Antinori, A
    AIDS, 2003, 17 (07) : 1099 - 1102
  • [5] Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors:: indirect comparison of controlled trials
    Yazdanpanah, Y
    Sissoko, D
    Egger, M
    Mouton, Y
    Zwahlen, M
    Chêne, G
    BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7434): : 249 - 253
  • [6] Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study)
    Brown, Jennifer A.
    Nsakala, Bienvenu L.
    Mokhele, Kuena
    Rakuoane, Itumeleng
    Muhairwe, Josephine
    Urda, Lorena
    Amstutz, Alain
    Tschumi, Nadine
    Klimkait, Thomas
    Labhardt, Niklaus D.
    HIV MEDICINE, 2022, 23 (03) : 287 - 293
  • [7] Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection
    Haubrich, Richard H.
    Riddler, Sharon A.
    Ribaudo, Heather
    DiRenzo, Gregory
    Klingman, Karin L.
    Garren, Kevin W.
    Butcher, David L.
    Rooney, James F.
    Havlir, Diane V.
    Mellors, John W.
    AIDS, 2011, 25 (18) : 2269 - 2278
  • [8] Viral Suppression Following Switch to Second-line Antiretroviral Therapy: Associations With Nucleoside Reverse Transcriptase Inhibitor Resistance and Subtherapeutic Drug Concentrations Prior to Switch
    Johnston, Victoria
    Cohen, Karen
    Wiesner, Lubbe
    Morris, Lynn
    Ledwaba, Johanna
    Fielding, Katherine L.
    Charalambous, Salome
    Churchyard, Gavin
    Phillips, Andrew
    Grant, Alison D.
    JOURNAL OF INFECTIOUS DISEASES, 2014, 209 (05): : 711 - 720
  • [9] A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial
    MacArthur, Rodger D.
    Novak, Richard M.
    Peng, Grace
    Chen, Li
    Xiang, Ying
    Hullsiek, Katherine Huppler
    Kozal, Michael J.
    van den Berg-Wolf, Mary
    Henely, Christopher
    Schmetter, Barry
    Dehlinger, Marjorie
    LANCET, 2006, 368 (9553): : 2125 - 2135
  • [10] Dolutegravir efficacy in achieving HIV viral load suppression after shifting from Non-nucleoside reverse transcriptase inhibitor based regimens: An Egyptian crosssectional study
    Sherif, M.
    Mohamed, R.
    Hatem, A.
    Al Sehemy, L.
    Abdelraouf, M. Ismail
    Al-Sharif, A. M.
    El Garhy, N.
    Awad, R. Awad
    Hamdy, M. Salah Eldin
    Esmat, G.
    El Khateeb, E.
    Sayed, A. M.
    Cordie, A.
    HIV MEDICINE, 2023, 24 : 94 - 95
123